AvatarPeak Bggrflipped into Biotech InvestingAvatarAvatarMar 22EU delays decision on Eisai-Biogen Alzheimer’s drugverified_publisherSeeking Alpha - Preeti SinghThe European Union's drug regulator has delayed it decision on Eisai (OTCPK:ESALF) (OTCPK:ESAIY) and partner Biogen's (NASDAQ:BIIB) breakthrough …
AvatarTipRanksflipped into TipRanks LabsFlipboardIcon version of the Flipboard logo6 days agoEisai says CHMP oral explanation for lecanemab rescheduledtipranks.com - TheFlyBiogen (BIIB) noted that Eisai (ESAIY) announced an update on the regulatory review process of lecanemab by the European Medicines Agency, or EMA. …
AvatarTipRanksflipped into TipRanks LabsFlipboardIcon version of the Flipboard logo1 day agoRBC Capital Remains a Buy on Neumora Therapeutics, Inc. (NMRA)tipranks.com - Brian AndersonIn a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report), with a …
AvatarInvestor's Business Dailyflipped into Financial & Business NewsFlipboardIcon version of the Flipboard logo1 day agoAlzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?investors.com - ALLISON GATLINThe quest to treat Alzheimer's disease is heating up as drugmakers Eli Lilly (LLY), Biogen (BIIB) and Roche (RHHBY) blaze new trails. But there are …
AvatarTipRanksflipped into TipRanks LabsFlipboardIcon version of the Flipboard logo4 days agoTruist Financial Reaffirms Their Buy Rating on Biogen (BIIB)tipranks.com - Howard KimTruist Financial analyst Robyn Karnauskas maintained a Buy rating on Biogen (BIIB – Research Report) today. The company’s shares closed last Friday …
FlipboardIcon version of the Flipboard logo4 days agoResting state functional connectivity modifications in monoaminergic circuits underpin fatigue development in patients with multiple sclerosisnature.com - Monica Margoni, Paola Valsasina, Anna Bacchetti, Damiano Mistri, Paolo Preziosa, Maria A. Rocca, Massimo FilippiDysregulation of monoaminergic networks might have a role in the pathogenesis of fatigue in multiple sclerosis (MS). We investigated longitudinal …
AvatarThomas Varnedoe IIflipped into HealthcareAvatarAvatar3 days agoPharmalittle: We're reading about a Novo Nordisk deal, a Regeneron setback, and moreSTAT - Ed SilvermanGood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so familiar …
AvatarNutritionFactsflipped into NutritionFactsFlipboardIcon version of the Flipboard logo1 day agoWhat’s on That Label? | NutritionFacts.orgnutritionfacts.orgToday, we take a deep dive into drugs and supplements that don’t work as advertised. And, we start with a deceptive dementia drug called …
Avatargeowarnerflipped into Digital Transformation AI ML Cloud ChatGPTAvatarAvatarAI Impact Tour arrives in Boston on March 27: A focus on data integrity in generative AIverified_publisherVentureBeat - Matt MarshallOn March 27, we’ll host the next installment of our AI Impact Tour in Boston, focusing on the practical application of generative AI in enterprise settings, with a particular emphasis on the critical role of data integrity. Caroline Arnold, CIO of State Street, and David Clifford, the head of data …
AvatarBankrateflipped into Recession WatchFlipboardIcon version of the Flipboard logo10 stocks near their 52-week lowbankrate.com - Brian Baker, CFAWith the stock market trading near all-time highs, investors may be struggling to find attractive bargains. Companies trading near their 52-week low …
AvatarWINK Newsflipped into WINK NewsFlipboardIcon version of the Flipboard logo1 day agoGroundbreaking Alzheimer’s drug being dropped by manufacturerwinknews.com - Amy OshierFORT MYERS The drug Aduhelm has a complicated history. It was greeted with great hope as a treatment for early-stage Alzheimer’s disease. In 2021, …
AvatarUSA TODAYAvatarAvatarMar 206.9 million Americans have Alzheimer's disease: How to reduce your riskverified_publisherUSA TODAY - Ken AlltuckerA new report estimates 6.9 million older Americans are living with Alzheimer’s disease in 2024, an increase of about 200,000 cases of the mind-robbing disease from 2023 and "a significant public health crisis," according to an expert. Another 5 million to 7 million adults have mild cognitive …